[an error occurred while processing this directive]
International Journal of Infectious Diseases: Volume 1, Number 3
Protection against Pertussis with a Monocomponent Pertussis Toxoid Vaccine
John Taranger, MD; Birger Trollfors, MD; Teresa Lagergård, PhD; and John B. Robbins, MD

Int J Infect Dis 1997; 1(3):148-151.

This study was undertaken to assess the safety and protective efficacy against pertussis of a monocomponent pertussis toxoid vaccine in a society with hyperendemic pertussis. A total of 3450 healthy infants from child health centers in the Gšteborg area of Sweden were enrolled in a double-blind, randomized, placebo-controlled study. A combined diphtheria-tetanus vaccine was given with or without pertussis toxoid (DTP-toxoids vs DT-toxoids) at 3, 5, and 12 months of age. One week after each vaccination a telephone interview about reactions was performed. From the day of the first vaccination a nasopharyngeal culture and acute and convalescent sera were obtained from study children and family members with cough lasting 7 or more days. Coughing episodes were classified according to the World Health Organization (WHO) definition of pertussis. There were no serious reactions. There were slightly more local reactions with DTP-toxoids than with DT-toxoids. During the period of blinded follow-up, which began from 30 days after the third vaccination and lasted on average for 17.5 months, the general vaccine efficacy was 71% (95% confidence interval (CI), 63-78%), and during an extended period of open follow-up performed during 6 months, vaccine efficacy was 77% (95% CI, 65-85%). The efficacy against household exposure during the same periods was 73% (95% CI, 61-83%) and 76% (95% CI, 51-91%), respectively. A hydrogen-peroxide inactivated pertussis toxoid vaccine that is easily standardized is safe and confers substantial protection against pertussis.

Key Words: efficacy, pertussis, toxoid, vaccine

Back to Table of Contents

The International Journal of Infectious Diseases is owned by
the International Society for Infectious Diseases.
The Journal is published quarterly for the ISID by B.C. Decker Inc.